The Coronavirus disease (COVID-19) is a terrible global pandemic. With our drug candidate APN01, APEIRON Biologics is proud to be among the leading Biotech firms globally, to work on the development of a therapeutic to fight SARS-Cov-2.   The story of APN01 APN01 was developed after the first SARS outbreak in the early 2000s. Recently,...

Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada. 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01 APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical...